These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26348533)

  • 21. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
    Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
    J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
    Wang Z; Tadayasu Y; Hu N; Shu S; Hu C; Luo Z
    Pulm Pharmacol Ther; 2020 Aug; 63():101944. PubMed ID: 32916296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
    Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA).
    Bjermer L; Kuna P; Jorup C; Bengtsson T; Rosenborg J
    Drug Des Devel Ther; 2015; 9():753-62. PubMed ID: 25709399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
    Beeh KM; LaForce C; Gahlemann M; Wenz A; Toorawa R; Fležar M
    Respir Res; 2015 Jul; 16(1):87. PubMed ID: 26177937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355.
    Diderichsen PM; Cox E; Martin SW; Cleton A; Ribbing J
    Clin Pharmacokinet; 2013 Jun; 52(6):443-52. PubMed ID: 23494982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study Design of VESUTO
    Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
    Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.
    Muruganandan S; Jayaram L
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1179-89. PubMed ID: 26124657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
    Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ▼Olodaterol--another LABA for COPD.
    Drug Ther Bull; 2015 Apr; 53(4):42-5. PubMed ID: 25858815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S
    Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.
    Jiang J; Li L; Yin H; Woessner R; Emotte C; Li R; Khindri S; Pei H
    Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):203-8. PubMed ID: 24705947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.
    Lee HW; Kim HJ; Lee CH
    Br J Clin Pharmacol; 2017 Jun; 83(6):1166-1175. PubMed ID: 27957746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.